Paeds Vivas · cardiology
Pulmonary hypertension in children — branching viva
Branching viva on pulmonary hypertension in children: the haemodynamic definition, the WHO classification, the echocardiographic and catheter-based diagnosis, the three drug pathways, the Eisenmenger threshold, and the surgical escalations.
On this page & tools
Target exams
Branch 1 — Definition and classification
The candidate opens by defining pulmonary hypertension as a mean pulmonary artery pressure above twenty at cardiac catheterisation, with pulmonary arterial hypertension adding a raised resistance and a normal wedge pressure. They then name the five WHO groups and explain why congenital heart disease and bronchopulmonary dysplasia dominate the paediatric caseload. [3] [2]
Branch 2 — Diagnosis and the role of the catheter
The examiner probes why echocardiography is first-line but the catheter is the gold standard. The candidate explains that the echo estimates the pressure from the tricuspid regurgitation velocity and assesses the right ventricle, while the catheter confirms the diagnosis, measures the wedge pressure and the indexed resistance, and tests for vasoreactivity with inhaled nitric oxide. They stress that the wedge pressure is the safeguard against treating left heart disease. [1] [4]
Branch 3 — The three drug pathways and risk stratification
The candidate explains the three imbalanced endothelial pathways — nitric oxide and prostacyclin falling while endothelin rises — and the matching drugs: phosphodiesterase-5 inhibitors, prostacyclin analogues, and endothelin receptor antagonists. They describe the risk stratification into low, intermediate, and high risk, and why the high-risk child with right ventricular failure is escalated to parenteral prostacyclin. [5] [10]
Branch 4 — The Eisenmenger threshold
The examiner branches to the teenager with the late-repaired ventricular septal defect and the fixed resistance. The candidate explains that the catheter, not the echo, decides operability, that repairing a shunt above the threshold removes the pop-off and worsens the failure, and that the Eisenmenger physiology is irreversible. They outline the management with targeted therapy and the avoidance of pregnancy. [8] [5]
Branch 5 — Surgical escalation
The final branch covers the refractory child. The candidate describes the atrial septostomy as a pop-off that decompresses the right ventricle, the Potts shunt as reserved for the suprasystemic idiopathic form, and lung transplantation as the final option. They close on the principle that the right ventricle, not the pressure number, decides the prognosis. [4] [2]
References
- [1]Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation, 2015.PMID 26534956
- [2]Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J, 2019.PMID 30545978
- [3]Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J, 2019.PMID 30545968
- [4]Hansmann G, Koestenberger M, Alastalo TP, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension. J Heart Lung Transplant, 2019.PMID 31495407
- [5]Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol, 2013.PMID 24355636
- [8]Arvanitaki A, Gatzoulis MA, Opotowsky AR, et al. Eisenmenger Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol, 2022.PMID 35331414
- [10]Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation, 2012.PMID 22128226